Disponible en / Available in:
Español
The Respiralia Foundation and the Balearic Association of Cystic Fibrosis celebrate the agreement between the Ministry of Health and Vertex for the financing of Orkambi and Symkevi medicines for Cystic Fibrosis.
Representatives of the Cystic Fibrosis Spanish Federation (FEFQ) have held a meeting with the Minister of Health, Consumption and Social Welfare, Excma. Mrs. Mª Luisa Carcedo and the General Director of Basic Portfolio of Services of the National Health and Pharmacy System, Mrs. Patricia Lacruz Gimeno, where they have personally communicated the agreement reached with the Vertex Pharmaceuticals laboratory for the financing of Orkambi, Symkevi and Kalydeco drugs, which will be available from next November 1st.
In the case of Orkambi, the indication for children aged 6 to 11 years (both inclusive) with two copies of the F508del mutation has been authorized. And in the case of Symkevi, its use has been authorized for people from 12 years of age with two copies of the F508del mutation, as well as people with a single F508del copy plus one of the following 14 residual function mutations: P67L, R117C, L206W , R352Q, A455E, D579G, 711 + 3A → G, S945L, S977F, R1070W, D1152H, 2789 + 5G → A, 3272-26A → G, and 3849 + 10kbC → T.
This decision was taken at the last meeting of the Interministerial Commission on Drug Prices, held on September 30 and, unlike previous resolutions, has been accepted by the Vertex laboratory.
The meeting was attended by Blanca Ruiz (president of the FEFQ), Cristina Simal (secretary), Juan Da Silva and Fernando Moreno (both vice-presidents), who have been really excited to receive the news, after almost 4 years of struggle for Access to these medications.
